Cidara Therapeutics Management

Management criteria checks 2/4

Cidara Therapeutics' CEO is Jeff Stein, appointed in Jan 2014, has a tenure of 10.83 years. total yearly compensation is $1.56M, comprised of 38.1% salary and 61.9% bonuses, including company stock and options. directly owns 1.03% of the company’s shares, worth €1.41M. The average tenure of the management team and the board of directors is 3.5 years and 3.8 years respectively.

Key information

Jeff Stein

Chief executive officer

US$1.6m

Total compensation

CEO salary percentage	38.1%
CEO tenure	10.8yrs
CEO ownership	1.0%
Management average tenure	3.5yrs
Board average tenure	3.8yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Jeff Stein's remuneration changed compared to Cidara Therapeutics's earnings?
Date	Total Compensation	Salary	Company Earnings
Sep 30 2024	n/a	n/a	-US$124m
Jun 30 2024	n/a	n/a	-US$112m
Mar 31 2024	n/a	n/a	-US$24m
Dec 31 2023	US$2m	US$594k	-US$23m
Sep 30 2023	n/a	n/a	-US$34m
Jun 30 2023	n/a	n/a	-US$18m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$1m	US$566k	-US$34m
Sep 30 2022	n/a	n/a	-US$33m
Jun 30 2022	n/a	n/a	-US$63m
Mar 31 2022	n/a	n/a	-US$44m
Dec 31 2021	US$2m	US$566k	-US$42m
Sep 30 2021	n/a	n/a	-US$47m
Jun 30 2021	n/a	n/a	-US$47m
Mar 31 2021	n/a	n/a	-US$74m
Dec 31 2020	US$1m	US$542k	-US$75m
Sep 30 2020	n/a	n/a	-US$67m
Jun 30 2020	n/a	n/a	-US$47m
Mar 31 2020	n/a	n/a	-US$42m
Dec 31 2019	US$1m	US$526k	-US$41m
Sep 30 2019	n/a	n/a	-US$39m
Jun 30 2019	n/a	n/a	-US$56m
Mar 31 2019	n/a	n/a	-US$69m
Dec 31 2018	US$1m	US$501k	-US$69m
Sep 30 2018	n/a	n/a	-US$70m
Jun 30 2018	n/a	n/a	-US$69m
Mar 31 2018	n/a	n/a	-US$59m
Dec 31 2017	US$2m	US$460k	-US$56m

Compensation vs Market: Jeff's total compensation ($USD1.56M) is above average for companies of similar size in the German market ($USD471.55K).

Compensation vs Earnings: Jeff's compensation has increased whilst the company is unprofitable.

CEO

Jeff Stein (69 yo)

10.8yrs

Tenure

US$1,558,544

Compensation

Dr. Jeffrey L. Stein, Ph D., also known as Jeff, has been the Chief Executive Officer, President and Executive Director of Cidara Therapeutics, Inc. since January 2014. Dr. Stein served as Principal Financ...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Jeffrey Stein	President	10.8yrs	US$1.56m	1.03% € 1.4m
Shane Ward	COO & Corporate Secretary	3.3yrs	US$929.86k	0.073% € 100.6k
Taylor Sandison	Chief Medical Officer	8.2yrs	US$884.09k	0.18% € 250.7k
Kevin Forrest	Founder & Chief Strategy Officer	no data	US$613.24k	no data
Preetam Shah	CFO & Principal Accounting Officer	3.2yrs	US$683.71k	0.11% € 147.2k
Allison Lewis	Senior Vice President of People & Culture	3.8yrs	no data	no data
Leslie Tari	Chief Scientific Officer	5.7yrs	US$1.39m	0.12% € 165.0k
Nicole Davarpanah	Senior VP of Translational Research & Development	1.3yrs	no data	no data
Jim Beitel	Chief Business Officer	less than a year	no data	no data

3.5yrs

Average Tenure

51.5yo

Average Age

Experienced Management: 20D0's management team is considered experienced (3.5 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Jeffrey Stein	President	10.8yrs	US$1.56m	1.03% € 1.4m
Daniel Burgess	Independent Chairman of the Board	10.6yrs	US$126.84k	0.0021% € 2.9k
Theodore Schroeder	Independent Director	10.6yrs	US$98.84k	0% € 0
Frederick Hayden	Member of the Scientific Advisory Board	4.3yrs	no data	no data
Bonnie Bassler	Independent Director	3.8yrs	US$86.84k	0.00021% € 289.9
Carin Canale-Theakston	Independent Director	3.8yrs	US$82.34k	0% € 0
Chrysa Mineo	Independent Director	6.7yrs	US$91.34k	0% € 0
Ryan Spencer	Independent Director	less than a year	no data	no data
James Merson	Independent Director	less than a year	no data	no data
Laura Tadvalkar	Independent Director	less than a year	no data	no data
Mario Barro	Member of Scientific Advisory Board	less than a year	no data	no data
Philip Krause	Member of Scientific Advisory Board	less than a year	no data	no data

3.8yrs

Average Tenure

62yo

Average Age

Experienced Board: 20D0's board of directors are considered experienced (3.8 years average tenure).

Cidara Therapeutics Management

Management criteria checks 2/4

Key information

Recent management updates

Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members

Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

High number of new directors

Cidara Therapeutics, Inc. Announces Executive Changes

Recent updates

Cidara Therapeutics, Inc. announced that it expects to receive $104.999685 million in funding from a group of investors

Cidara Therapeutics, Inc. Announces the Appointment of Scientific Advisory Board Members

Cidara Therapeutics, Inc. Announces Reduction in Workforce to Focus on Planned Clinical Development of CD388

Cidara Therapeutics Appoints Jim Beitel as Chief Business Officer

Cidara Therapeutics, Inc.(NasdaqCM:CDTX) dropped from Russell 3000E Value Index

Cidara Therapeutics, Inc., Annual General Meeting, Jul 18, 2024

Cidara Therapeutics Regains Compliance with Nasdaq Continued Listing Rules

Napp Pharmaceutical Group Ltd. acquired All assets and rights related to REZZAYO of Cidara Therapeutics, Inc. (NasdaqCM:CDTX).

Cidara Therapeutics, Inc. announced that it expects to receive $240 million in funding from RA Capital Management, L.P., Canaan Management, Inc., BVF Partners L.P. and other investors

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. announced delayed annual 10-K filing

Cidara Therapeutics, Inc. Announces Approval of REZZAYO by the MHRA for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics Announces Completion of Enrollment in Phase 3 Restore Trial of Rezafungin in China

Melinta Therapeutics, Llc and Cidara Therapeutics, Inc. Announce Publication of Pooled Data from Phase 3 Pivotal Restore Trial & Phase 2 Strategic Trial of Rezafungin for Injection in the Lancet Id

Cidara Therapeutics Requests a Hearing Before the Nasdaq Hearings Panel

New minor risk - Profitability

Forecast to breakeven in 2025

Third quarter 2023 earnings released: US$0.091 loss per share (vs US$0.17 profit in 3Q 2022)

Cidara Therapeutics and Mundipharma Receive Positive CHMP Opinion for Rezafungin for the Treatment of Invasive Candidiasis in Adults

Cidara Therapeutics, Inc. Presents New Preclinical and Clinical Data on Novel Drug-Fc Conjugate CD388 at IDWeek 2023

New major risk - Financial position

Cidara Therapeutics, Inc. Appoints Nicole Davarpanah as Senior Vice President of Translational Research and Development

New minor risk - Profitability

Second quarter 2023 earnings released: US$0.14 loss per share (vs US$0.14 loss in 2Q 2022)

Forecast to breakeven in 2025

Cidara Therapeutics Provides Update on REZZAYO™ (Rezafungin for Injection)

New major risk - Share price stability

Cidara Therapeutics, Inc. Receives U.S. FDA Fast Track Designation for CD388, a Novel Drug-Fc Conjugate Targeting Influenza A and B

New minor risk - Market cap size

Cidara Therapeutics, Inc. to Present Highlights from Its Ongoing Preclinical Studies of CD421 as Well as the Development of Its Novel Drug-Fc Conjugates from Cidara’s Cloudbreak® Platform

First quarter 2023 earnings released: EPS: US$0.032 (vs US$0.27 loss in 1Q 2022)

Full year 2022 earnings released: US$0.43 loss per share (vs US$0.81 loss in FY 2021)

Cidara Therapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Cidara Therapeutics and Melinta Therapeutics Announce FDA Advisory Committee Recommends Approval of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Nominates First Oncology Clinical Development Candidate from Its Cloudbreak Platform

Cidara Therapeutics, Inc. and Melinta Therapeutics, LLC Announce Publication of Data from the Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis in The Lancet

High number of new directors

Third quarter 2022 earnings released: EPS: US$0.17 (vs US$0.36 loss in 3Q 2021)

Cidara Therapeutics Attends Hearing Before the Nasdaq Hearings Panel and Presents Plan to Regain Compliance with the Nasdaq Capital Market

Cidara Therapeutics, Inc. Announces FDA Acceptance for Priority Review of New Drug Application for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Cidara Therapeutics Announces Initiation of Phase 2A Human Viral Challenge Trial to Evaluate Cd388 for Universal Prevention of Influenza

Cidara Therapeutics, Inc. Announces Executive Changes

Second quarter 2022 earnings released: US$0.19 loss per share (vs US$0.18 profit in 2Q 2021)

Cidara Therapeutics, Inc. Submits New Drug Application to the U.S. Food and Drug Administration for Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

First quarter 2022 earnings released: US$0.27 loss per share (vs US$0.35 loss in 1Q 2021)

High number of new directors

Mundipharma and Cidara Therapeutics Announces First Presentation of Results from Global Phase 3 ReSTORE Trial of Rezafungin for Treatment of Candidemia and/or Invasive Candidiasis Demonstrating its Positive Efficacy and Safety Profile

Cidara Therapeutics, Inc. Announces Executive Changes

Cidara Therapeutics, Inc. Announces the Completion of Dosing the First Cohort of Healthy Volunteers in the Phase 1 Trial of CD388 in Development for Universal Prevention and Treatment of Seasonal and Pandemic Influenza

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

Medicines and Healthcare Products Regulatory Agency in the UK Grants Mundipharma and Cidara Therapeutics Inc.'s Rezafungin Promising Innovative Medicine Designation

Cidara Therapeutics, Inc. Announces FDA Acceptance of its Investigational New Drug Application for CD388 for Universal Prevention and Treatment of Influenza

Cidara Therapeutics, Inc. and Mundipharma Announce Positive Topline Results from Global Phase 3 Pivotal ReSTORE Trial of Rezafungin for Treatment of Candidemia and Invasive Candidiasis

President recently bought €69k worth of stock

Third quarter 2021 earnings released: US$0.36 loss per share (vs US$0.41 loss in 3Q 2020)

President recently bought €74k worth of stock

Cidara Therapeutics and Mundipharma Announces Completion of Enrollment in the Phase 3 ReSTORE Trial of Rezafungin for the Treatment of Candidemia and Invasive Candidiasis

Second quarter 2021 earnings released: EPS US$0.18 (vs US$0.45 loss in 2Q 2020)

Chief Financial Officer James Levine has left the company

Cidara Therapeutics Presents New Analyses from Multiple Rezafungin Studies at ECCMID 2021

Cidara Therapeutics, Inc.(NasdaqGM:CDTX) dropped from Russell Microcap Value Index

Forecast to breakeven in 2025

First quarter 2021 earnings released: US$0.39 loss per share (vs US$0.46 loss in 1Q 2020)

Full year 2020 earnings released: US$1.74 loss per share (vs US$1.41 loss in FY 2019)

Revenue misses expectations

Cidara Therapeutics, Inc. Announces New Data for Rezafungin At the 21st ICHS Symposium

New 90-day high: €2.23

Cidara Therapeutics, Inc. Announces Board Changes

Cidara Therapeutics, Inc. Appoints Christopher Kurtz as Executive Vice President of Technical Operations